Tier 1 and Tier 2 pharmaceutical companies put their primary effort into the largest opportunities; hence, late-life drugs and small drug programs get little support. Where new companies have been established to acquire and manage late-life drugs, the emphasis is on science - enhancing the original drug to prolong its life and/or appeal to a broader market segment.

Concurrently, the biotech space is a continuum of new drugs developed with a laser focus on science, but with few resources dedicated to business needs in anticipation of FDA approval. These companies are hampered by an inability to resource, organize, and fund infrastructure to support and prepare their product for the marketplace. By the time the drug is approved, they tend to add services all at once, which leads to both ineffective service provision and higher cost. This can be greatly mitigated if the services are phased in at earlier stages.

In both cases, there is need to provide an array of business services to support new, rehabilitated, or orphan drugs when they will have the most impact. A single provider of such services removes the current "ad hoc", and often suboptimal, selection process substituting a "go-to" solution. Additionally, a complete service offering allows us to see the big picture from a commercialization perspective, allowing an allocation of resources across the range of services that best meet the needs of the customer, as opposed to a potentially myopic viewpoint of a provider focused on a particular service offering.

Convergence 360 provides a full spectrum of integrated commercialization services to emerging Life Sciences companies. Our experience and perspective will enable our clients to chart a course for product and corporate success. Convergence 360's service offerings ensure our customers maximize their product and corporate launches; increasing execution speed and providing a structured and comprehensive approach throughout the entire commercialization process.

›››  How to Contact Us